01 Adoption of Expanded Antibiotic Testing PanelsThe antibiotic susceptibility testing market analysis highlights increasing laboratory demand for testing panels covering broader antibiotic combinations. Clinical laboratories are adopting comprehensive susceptibility panels to assess resistance against multiple antibiotics in a single testing process. Manufacturers are developing flexible testing platforms that accommodate newly approved antibiotics and updated susceptibility breakpoints.
02 Preference for Direct Blood Culture Susceptibility TestingHospital laboratories are increasingly adopting rapid susceptibility testing directly from positive blood cultures. This approach reduces dependence on conventional bacterial subculturing and supports earlier antibiotic selection for bloodstream infections. bioMérieux's VITEK REVEAL system can deliver susceptibility results for Gram-negative bacteria in approximately 5.5 hours.
01 Supply chain disruptions are expected to have a moderate impact on the antibiotic susceptibility testing market share due to shortages of testing reagents, antibiotic discs, culture media, and laboratory consumables. The market is expected to experience a K-shaped recovery as established manufacturers with diversified supplier networks can restore operations faster. The market is projected to grow at a CAGR of 5.62%, but supply constraints could lower short-term growth by 1.0 percentage point to 4.62% under an illustrative disruption scenario. Improved reagent availability and stable distribution networks could support recovery toward 5.62%.
01 The antibiotic susceptibility testing market forecasts continued investment in rapid diagnostic technologies and automated testing systems. In May 2026, iFAST Diagnostics announced USD 6.7 million funding to support rapid AST commercialization, European regulatory approval, and US clinical development.
01 Prevalance of Antibiotic Resistant Bacterial Infections and Rising Adoption of Invasive Arterial Monitoring in High-Risk Surgeries Drives MarketPrevalence of antibiotic-resistant bacterial infections is strengthening demand for antibiotic susceptibility testing across hospitals and diagnostic laboratories. Antibiotic resistance in common pathogens such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus is increasing the need for accurate susceptibility assessment. Thus, the need for targeted antibiotic therapy supports demand for automated susceptibility testing systems and laboratory consumables.Implementation of antimicrobial stewardship programs in hospitals is strengthening demand for antibiotic susceptibility testing. These programs encourage clinicians to use laboratory results for appropriate antibiotic selection and reduce unnecessary broad-spectrum treatment. The U.S. CDC's hospital stewardship framework recommends selective reporting of susceptibility results to guide antibiotic prescriptions.
01 High Automated Testing Costs and Frequent Susceptibility Breakpoint Revisions Restrain Market ExpansionAutomated antibiotic susceptibility testing systems require substantial investment in laboratory equipment and ongoing maintenance. Additional expenditure on proprietary reagent cards and quality control materials increases testing costs. These financial barriers restrict the adoption of automated systems in resource-constrained healthcare facilities.Regular revisions to antibiotic susceptibility breakpoints create operational challenges for clinical laboratories. Updated interpretation criteria require laboratories to review testing procedures and verify compatibility with existing instruments. Manufacturers also face additional technical requirements to maintain the clinical accuracy of susceptibility testing systems.
01 Microfluidic-Based Rapid Phenotypic Testing and Decentralized Antibiotic Susceptibility Testing Offers Growth OpportunitiesNeed for faster antibiotic treatment decisions in hospitals is encouraging investment in rapid phenotypic susceptibility testing. According to EUCAST, rapid susceptibility testing directly from positive blood cultures can provide results within 4–8 hours of incubation. This demand provides manufacturers with opportunities to commercialize microfluidic-based testing platforms, expand rapid testing portfolios, and secure contracts with hospital laboratories seeking faster diagnostic results.Limited availability of microbiology laboratories in underserved regions presents expansion opportunities for antibiotic susceptibility testing manufacturers. Smaller hospitals and healthcare facilities often depend on centralized laboratories, creating demand for accessible and cost-effective testing solutions. Market players can target these facilities with portable susceptibility testing instruments, simplified workflows, and affordable consumables.